Metral
Markets

AbbVie is buying an eczema and asthma drug developer for nearly $11 billion

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis

M
Metral Newsroom
Editorial Desk
· 2 min read
𝕏 in ✉
AbbVie is buying an eczema and asthma drug developer for nearly $11 billion

AbbVie is buying an eczema and asthma drug developer for nearly $11 billion

Published June 22, 2026 · Category: Markets

Overview

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis

Source

Originally published at qz.com.

Related Articles

CD
Metral Newsroom

Metral covers global markets, stocks, crypto and the economy — desk research and data-driven analysis. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.

Related Stories

More from Financial News →
Micron ties its future to Anthropic in supply deal
Markets

Micron ties its future to Anthropic in supply deal
Oil prices fall after US waives Iran sanctions and peace talks in Switzerland progress – business live
Markets

Oil prices fall after US waives Iran sanctions and peace talks in Switzerland progress – business live
Australia's coal and gas exports violate our human rights, group says in new UN case
Markets

Australia's coal and gas exports violate our human rights, group says in new UN case
Amazon is selling a 2-in-1 laptop and tablet for just $73 during Prime Day
Markets

Amazon is selling a 2-in-1 laptop and tablet for just $73 during Prime Day